ClinicalTrials.gg
CompletedNCT01432665Updated Jul 29, 2013

Lybrido for Female Sexual Dysfunction

A Phase 2 interventional study of Placebo and Sildenafil in Hypoactive Sexual Desire Disorder, sponsored by Emotional Brain NY Inc.. Completed at 14 sites in United States. Open to female participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-29.

Sponsored by Emotional Brain NY Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing testosterone in Sexual Dysfunctions, Psychological — 1 open to participants now, 1 under way, none of them phase 3. Testosterone · Sexual Dysfunctions, Psychological.

Enrollment
13th of 17
196 · median 549
Started
2011
with 1 other
Phase 2
4 of 17
1 open now
Registered
15th of 17
by date
Lead sponsor
2 of 17
Emotional Brain NY Inc.

Among the 17 studies testing testosterone in Sexual Dysfunctions, Psychological, this one is the 13th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 15th registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

1 of the 17 studies testing testosterone in Sexual Dysfunctions, Psychological is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About testosterone

Testosterone: first FDA approval 1953 (DELATESTRYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 21 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing testosterone in Sexual Dysfunctions, Psychological, or all of them as a file.
02

Study summary

The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study. Subjects are randomly to one of seven treatment arms. The study investigates the effective dose of Lybrido in increasing the number of satisfactory sexual episodes in the domestic setting in 210 healthy female subjects with hypoactive sexual desire disorder and low sensitivity for sexual cues (30 subjects per group).

03

Conditions studied

  • Hypoactive Sexual Desire Disorder

Keywords

  • HSDD
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written
  2. Female 21 to 70 years of age, inclusive, pre- or , with HSDD (comorbidity with female sexual arousal disorder and/or female orgasmic disorder [FOD; only as secondary diagnosis] is allowed). The diagnosis of HSDD will be established by a trained professional.
  3. Low sensitivity for sexual cues
  4. Be involved in a stable relationship and have a partner who will be at home for the majority of the study duration
  5. Healthy according to normal results of medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant

Exclusion criteria

Exclusion Criteria:

  1. Any underlying cardiovascular condition, including unstable angina pectoris, that would preclude sexual activity
  2. History of myocardial infarction, stroke, , or life-threatening arrhythmia within the prior 6 months
  3. Uncontrolled atrial fibrillation/flutter at screening or other significant abnormality observed on (ECG)
  4. Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure > 90 mmHg. For subjects > 60 years old and without diabetes mellitus, familial hypercholesterolemia, or cardiovascular disease: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure > 90 mmHg
  5. Systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg
  6. Use of oral containing anti-androgens
  7. Use of oral contraceptive containing 50 μg estrogen or more
  8. Positive test result for Chlamydia or gonorrhea
  9. Pregnancy or intention to become pregnant during this study (Note: A urine pregnancy test will be performed in all women prior to the administration of study medications.)
  10. Lactating or delivery in the previous 6 months
  11. Significant abnormal pap smear in the previous 12 months
  12. History of bilateral oophorectomy
  13. Other unexplained gynecological complaints, such as abnormal uterine bleeding patterns
  14. Liver and/or renal insufficiency ( and alanine aminotransferase > 3 times the and/or \< 29 mL/min based on the Cockcroft and Gault formula)
  15. Current clinically relevant endocrine disease or uncontrolled diabetes mellitus
  16. Current clinically relevant neurological disease which, in the opinion of the investigator, would compromise the validity of study results, or which could form a for sildenafil and/or testosterone use
  17. History of hormone-dependent
  18. Vision impairment, such as partial or complete blindness or color blindness
  19. Dyslexia
  20. Positive test result for , , or (acute and chronic hepatitis infection)
  21. History of (childhood) sexual abuse that, in the opinion of the investigator, could have negative psychological effects when testosterone is administered
  22. (Treatment for) a psychiatric disorder that, in the opinion of the investigator, would compromise the validity of study results or which could be a contraindication for sildenafil and/or testosterone use
  23. Current psychotherapeutic treatment for female sexual dysfunction
  24. Current sexual disorder of vaginismus or dyspareunia according to the , fourth edition (text revision).
  25. A substance abuse disorder that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study (Mild or moderate alcohol consumption is allowed but must be stopped 12 hours before the home measurement [Stroop task].)
  26. Positive test result for illicit drugs
  27. Use of potent inhibitors (eg, ritonavir, ketoconazole, itraconazole clarithromycin, erythromycin and saquinavir)
  28. Use of potent CYP3A4 inducers (eg, carbamazepine, phenytoin, phenobarbital, St John"s wort, rifampin)
  29. Use of nitrates or nitric oxide donor compounds
  30. Use of selective serotonin reuptake inhibitors, tricyclic antidepressants, or other antidepressants
  31. Use of any other medication that interferes with study medication (eg, monoamine oxidase [MAO] inhibitors [includes classic MAO inhibitors and linezolid])
  32. Use of medication (including herbs) that would compromise the validity of study results
  33. Use of testosterone therapy within 6 months before study entry
  34. Illiteracy, unwillingness, or inability to follow study procedures
  35. Participation in other clinical trials within the last 30 days
  36. Any other clinically significant abnormality or condition which, in the opinion of the investigator, might interfere with the participant"s ability to provide or comply with study instructions, compromise the validity of study results, or be a contraindication for sildenafil and/or testosterone use
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Placebo

    30 subjects administered a placebo

    Drug: Placebo

  • Experimental
    sildenafil + testosterone combination drug 1

    30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)

    Drug: Sildenafil · Drug: Testosterone

  • Experimental
    Sildenafil and testosterone combination drug 2

    Sildenafil 50mg and testosterone 0.25mg

    Drug: Sildenafil · Drug: Testosterone

  • Experimental
    Sildenafil and testosterone combination drug 3

    30 subjects are given sildenafil 25mg and testosterone 0.50mg

    Drug: Sildenafil · Drug: Testosterone

  • Experimental
    Sildenafil and Testosterone Combination drug 4

    30 subjects are given sildenafil 50mg and testosterone 0.50mg

    Drug: Sildenafil · Drug: Testosterone

  • Experimental
    Sildenafil 50mg

    30 subjects are given sildenafil 50mg

    Drug: Sildenafil

  • Experimental
    Testosterone 0.50mg

    30 subjects are given testosterone 0.5mg

    Drug: Testosterone

Interventions

  • DrugPlacebo

    Solid Oral Dosage. Maximum every other day (on an as needed basis)

  • Solid Oral Dosage. Maximum every other day (on an as needed basis)

  • Solid Oral Dosage. Maximum every other day (on an as needed basis)

06

What researchers measure

Primary outcomes

  1. The number of satisfactory sexual encounters based on event questionnaires on active drug as compared to placebo during double-blind treatment period episodes in the domestic setting.

    Efficacy is estimated by self reporting by subjects using daily event questionnaires, recorded within 24 hours after a sexual event. The number of events between a 4-week baseline establishment period will be compared with the number of events during the 8 week double-blind treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks.

    Time frame: 20 weeks

Secondary outcomes

  1. Sexual satisfaction

    Sexual satisfaction will be evaluated based on a global satisfaction assessment comparing the 4-week establishment period with the 8 week DB treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks.

    Time frame: 20 Weeks

  2. Sexual desire and arousal

    Sexual desire and arousal will be evaluated based on the 'desire' and 'arousal' domains of the Sexual Anamnesis Questionnaire, the Sexual Function questionnaire and weekly diaries throughout the course of the study.

    Time frame: 20 Weeks

  3. Sexual motivation and inhibition

    Sexual motivation and inhibition will be assessed using the Sexual Motivation Questionnaire and comparing sexual motivation and inhibition between the 4-week establishment period and the 8-week DB treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks.

    Time frame: 20 Weeks

  4. Safety and toleration

    Safety will be evaluated by: 1) AEs \[Number of patients reporting AEs, number of patients reporting drug related AEs\] 2)SAE \[Number of patients reporting SAEs, number of patients reporting drug related SAEs\]and 3) Changes in laboratory safety data \[Number of patients reporting abnormal lab safety data, number of patients reporting drug related abnormal lab safety data\]. These will be evaluated throughout the course of the study.

    Time frame: 20 Weeks

07

Study locations

14 sites
  • San Diego Sexual Medicine
    San Diego, California 92120, United States
  • The Center for Vulvovaginal Disorders
    Washington, District of Columbia 20037, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Segal Institute Women's Health Clinic
    North Miami, Florida 33161, United States
  • Compass Research
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Meridien Research
    St Petersburg, Florida 34203, United States
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
  • Annapolis Sexual Wellness Center
    Annapolis, Maryland 21401, United States
  • Maryland Prime Care Physicians
    Stevensville, Maryland 21666, United States
  • Center for Sexual Medicine at Sheppard Pratt
    Townson, Maryland 22104, United States
  • Women's Health Research Center
    Plainsboro, New Jersey 08536, United States
  • Michael A. Werner, MD PC
    Purchase, New York 10577, United States
  • Philadelphia Clinical Research
    Philadelphia, Pennsylvania 19114, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011 and a primary completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2011
First posted
Sep 13, 2011
Start
Sep 2011
Primary completionActual
May 2013
Last update
Jul 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01432665
Lead sponsor
Emotional Brain NY Inc.
Responsible party
Sponsor
First posted
Sep 13, 2011
Start date
Sep 2011
Primary completion
May 2013
Last update
Jul 29, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sildenafil · Testosterone

Start the discussion